Cardiovascular Safety of the Selective μ-Opioid Receptor Antagonist Naloxegol: A Novel Therapy for Opioid-Induced Constipation.

William B WhitePeter KoweyUlysses DivaMark SostekRaj Tummala

Published in: Journal of cardiovascular pharmacology and therapeutics (2018)

These data demonstrate that naloxegol has a CV safety profile comparable to placebo/usual care in patients with OIC. Although the observed number of events was low, the data show no CV signal in patients with OIC treated with naloxegol.

Keyphrases

pain management
chronic pain
electronic health record
big data
healthcare
palliative care
randomized controlled trial
clinical trial
drug induced
oxidative stress
deep learning
study protocol
newly diagnosed
health insurance
irritable bowel syndrome